Effect of IONM on Efficacy and Safety Using Sugammadex in Thyroid Surgery

Sponsor
Lütfiye Nuri Burat Government Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT03634956
Collaborator
(none)
2
1
1
7
0.3

Study Details

Study Description

Brief Summary

Thyroidectomy is a frequently performed surgeon by the head and neck and endocrine surgeons. In recent years, surgical techniques and technological developments have resulted in a significant reduction in complication rates. Despite these advances, there is still a great deal of anxiety about the sound problems that can be experienced in patients after surgery. In the past years,the investigators have tried to prevent recurrent nerve paralysis by using intraoperative nerve monitoring (IONM). The use of IONM has begun to be preferred by many surgeons in the investigator's country. However, the use of IONM decreases the number of recurrent nerve paralysis are still being discussed and many studies have been done. In this study, it is aimed to prevent the formation of recurrent nerve paralysis in order to safely carry out the IONM by removing the effects of neuromuscular blockade drugs using sugammadex sodium medicine in the thyroidectomy operations.

Condition or Disease Intervention/Treatment Phase
  • Drug: Group B. Sugammadex sodium-IONM
N/A

Detailed Description

Patients who will undergo thyroidectomy using the IONM in the General Surgery Clinic of Istanbul, Bakırköy Dr.Sadi Konuk Training and Research Hospital. In this prospective observational clinical trial, the patients will be divided into two groups and the study will be performed as randomize. Randomization Patients who arrive consecutively, will be included in the study group (Group I IONM, group B IONM-sugammadex sodium). In both groups, anesthesia induction should be done with 3 mg / kg propofol, 2 ugr / kg fentanyl, 0.6 mg / kg rocuronium bromide, as the intubation tube, the number appropriate for the patient, After reaching the throat loom, the patient is entrapped and then the operation is started. After reaching the thyroid loin and hanging the throid with the swab sutures, the lobe is taken out with the finger maneuver and then the vascular nerve packet is dissected and the vagal nerve is exposed. IONM(Medtronic-NIM) were detected in the recurrent nerve thyroglossal groove and 100 microvolts or more were measured with nerve monitoring. + Acceptance of resection was started and IONM After the intubation of the group B-sugammadex sodium was started, the left hand ulnar sinus TOF-Guard device was placed and operation started. After reaching the thyroid loops and hanging the throids with hanging sutures and removing the lobe with finger maneuver, the vascular nerve was disassembled and the vagal nerve was dislocated. Then the electrical value was recorded with IONM and sugammadex sodium 2 mg / kg was made. and the TOF response at 4th minute is over 90% of the value to be measured and if the IONM is 100 microvolts higher, the recurrent nerve is found in the troglossal groove and the nerve is followed with the IONM and the resection procedure is started and the tirodidectomy will be performed. V0: vagal nerve initial value; V1: value before troid resection; V2: value after troid resection; R1: value after troid resection, R2: value after troid resection. Preoperative and postoperative vocal cord examination will be examined by otolaryngologist. Size, weight, sex, ASA scores, operation times, complications will be recorded. If there is no signal in RLN with intraoperative IONM and RLN paralysis will be accepted if there is inactivity in the vocal cord at the 1st postoperative ENT specialist vocal cord examinations. RLN paralysis will be accepted if there is inactivity in the cord at the vocal cord examination of the postoperative specialist ENT specialist. The ENT specialist and general surgeon will follow up and if the vocal cord is still in motion, the permanent RLN will be considered a paralysis.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
2 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Group A. Sugammadex sodium-IONM in thyroid surgery Group B.Standart technique-IONM in thyroid surgeryGroup A. Sugammadex sodium-IONM in thyroid surgery Group B.Standart technique-IONM in thyroid surgery
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Reversal of Rocuronium-Induced Neuromuscular Blockade by Sugammadex Increase for Efficiency of Intraoperative Neural Monitoring in the Thyroid Surgery
Actual Study Start Date :
Aug 14, 2018
Anticipated Primary Completion Date :
Feb 14, 2019
Anticipated Study Completion Date :
Mar 14, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Group I.IONM in thyroid surgery

Group I.IONM in thyroid surgery.Once the vagus has been detected,nerve conduction data will be detected with IONM. If the muscle relaxant effect is not detected, it will be detected with TOF device.

Drug: Group B. Sugammadex sodium-IONM
Group B.the vagal nerve is detected and then 2 mg / kg of sugammadex sodium is administered to remove the muscle relaxant effect
Other Names:
  • Sugammadex sodium intervention group
  • Outcome Measures

    Primary Outcome Measures

    1. Vocal cord paralysis [postop 15th days]

      postoperative vocal cord examination will be performed and the recurrent laryngeal nerve will be examined.

    Secondary Outcome Measures

    1. vagal nerve conduction value(V1) [15 to 45 minutes of surgery]

      V1: value to receive enough nerve conduction for IONM use from the vagus nerve

    2. vagal nerve conduction value after lob resection(V2) [30 to 90 minutes of surgery]

      V2:Vagus value after resection of thyroid lobe

    3. first detected vagal nerve conduction value(V0) [5 to 25 minutes of surgery]

      initial value after vagus sinus is detected

    4. TOF time [10 to 90 minutes of surgery]

      the time that the muscle relaxant is shown by the peripheral nerve stimulator whose effect has disappeared.TOF>0.9

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Clinical diagnosis of Multinodular goiter,

    • Clinical diagnosis of thyroid cancer

    • Clinical diagnosis of noduler goatr,

    • Clinical diagnosis of basedow Graves disease,

    Exclusion Criteria:
    • Patients with bleeding diathesis,

    • Patients who have previously undergone laryngeal surgery (vocal polyps, nodules or laryngeal cancer),

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Lutfiye NBGH İstanbul Turkey 34300

    Sponsors and Collaborators

    • Lütfiye Nuri Burat Government Hospital

    Investigators

    • Principal Investigator: Turgut Donmez, surgeon, Lütfiye Nuri Burat Goverment Hastanesi

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    TURGUT DONMEZ, Principal investigator, Lütfiye Nuri Burat Government Hospital
    ClinicalTrials.gov Identifier:
    NCT03634956
    Other Study ID Numbers:
    • BakirköyEAH 1
    First Posted:
    Aug 17, 2018
    Last Update Posted:
    Aug 20, 2018
    Last Verified:
    Aug 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by TURGUT DONMEZ, Principal investigator, Lütfiye Nuri Burat Government Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 20, 2018